Board of Directors

Toby Wilson Waterworth(BSc (Econ), BFP, FCA)

Chief Executive Officer

Toby is a strategic leader and healthcare entrepreneur with a track record of founding and building successful private and listed companies. This includes senior roles at Chiroscience Group plc (LSE) (acquired by Celltech Group plc (LSE) for $535m), Alizyme plc (AIM & LSE at a value of $340m), Expedeon (acquired by Sygnis AG) and Lipoxen plc ($24m AIM IPO and U.S. reverse merger).

Toby is a Fellow of the Institute of Chartered Accountants in England and Wales, Fellow of the Royal Society of Medicine, founder of the UK chapter of MIT Enterprise Forum and former advisor to the UK government in the development and commercialisation of healthcare innovations.

Robert Dow(BSc, MB CHB, FRCP (EDIN), FFPM)

Non-Executive Director

Dr Robert Dow is a senior biopharmaceutical executive with 39 years’ experience of product acquisitions and global clinical development having held senior roles at pharmaceutical and biotechnology companies, and contract research organizations (CROs). These include Head of Global Drug Development at Roche, and most recently, Chief Medical Officer PPD, one of the world’s leading CROs.

Charles Woler(MD, PhD)

Non-Executive Director

Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies and smaller, earlier stage companies.

He currently holds non-executive Chairman and non-executive Director positions in Europe and the U.S..

Previously Charles was Chairman and CEO of Roche France, Chairman of SmithKline Beecham’s European pharmaceutical business (UK), CEO of Cadus Pharmaceuticals (U.S.) and CEO of Biomnis (France).

Julian Thurston(MA (Oxon))

Non-Executive Director

Julian Thurston, with a 40-year career based in London, UK with multi-national law firms, is one of the top global lawyers specializing in commercial transactions in the pharmaceutical sector.  He has a particular focus on international collaborations and licensing agreements covering Europe, USA, China, Japan, and other emerging markets, and has advised and acted for numerous fast-growing healthcare companies.

William Ringo(MBA)

Board Advisor

Bill is an eminent pharma veteran with nearly 30 years experience of public markets, M&A, product commercialisation, and financial institutions.

He is currently Chairman of Assembly Biosciences Inc., and a director of Sangamo Therapeutics Inc., Immune Design Corp., Dermira Inc., and Five Prime Therapeutics Inc..

Previous roles include Chairman, CEO and President of NASDAQ-listed InterMune, Inc; SVP of Strategy and Business Development at Pfizer, Inc.; President and CEO of NASDAQ-listed Abgenix, Inc. Bill was also a member of Eli Lilly and Company’s operating committee.